Sanjivani Paranteral Ltd vs Sudeep Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Sanjivani Paranteral Ltd is ₹ 167.5 as of 05 May 15:30 . The P/E Ratio of Sanjivani Paranteral Ltd changed from 28.4 on March 2024 to 0 on March 2022 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Sudeep Pharma Ltd changed from 0 on March 2024 to 0 on March 2022 . This represents a CAGR of 0.0% over 4 years The Market Cap of Sanjivani Paranteral Ltd changed from ₹ 175.32 crore on March 2024 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 4 yearsThe Market Cap of Sudeep Pharma Ltd changed from ₹ 0 crore on March 2024 to ₹ 0 crore on March 2022 . This represents a CAGR of 0.0% over 4 years The revenue of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 22.36 crore as compare to the Sep '25 revenue of ₹ 15.66 crore. This represent the growth of 42.78% The revenue of Sudeep Pharma Ltd for the Dec '25 is ₹ 179.17 crore as compare to the Sep '25 revenue of ₹ 172.83 crore. This represent the growth of 3.67% The ebitda of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 4.13 crore as compare to the Sep '25 ebitda of ₹ 2.41 crore. This represent the growth of 71.37% The ebitda of Sudeep Pharma Ltd for the Dec '25 is ₹ 66.81 crore as compare to the Sep '25 ebitda of ₹ 65.63 crore. This represent the growth of 1.8% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 2.78 crore over 7 quarters. This represents a CAGR of 32.01% The net profit of Sudeep Pharma Ltd changed from ₹ 17.08 crore to ₹ 47.7 crore over 7 quarters. This represents a CAGR of 79.84% The Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Sudeep Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

About Sudeep Pharma Ltd

Sudeep Pharma Limited was incorporated as Sudeep Pharma Private Limited' as a private limited company dated December 21, 1989, issued by the Registrar of Companies, Ahmedabad.
Thereafter, Company was converted into a public limited company and the name of the Company was changed to Sudeep Pharma Limited' pursuant to fresh certificate of incorporation dated April 5, 1995, issued by the Assistant Registrar of Companies, Gujarat at Dadra & Nagar Haveli.
Company was subsequently converted back to a private limited company vide a fresh certificate of incorporation dated October 1, 2014 issued by the Assistant Registrar of Companies, Gujarat at Ahmedabad, and the name of Company was accordingly changed from Sudeep Pharma Limited' to Sudeep Pharma Private Limited'.
Further, Company was converted into a public limited company and consequently, the name of Company was changed to Sudeep Pharma Limited'.

FAQs for the comparison of Sanjivani Paranteral Ltd and Sudeep Pharma Ltd

Which company has a larger market capitalization, Sanjivani Paranteral Ltd or Sudeep Pharma Ltd?

Market cap of Sanjivani Paranteral Ltd is 205 Cr while Market cap of Sudeep Pharma Ltd is 7,747 Cr

What are the key factors driving the stock performance of Sanjivani Paranteral Ltd and Sudeep Pharma Ltd?

The stock performance of Sanjivani Paranteral Ltd and Sudeep Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanjivani Paranteral Ltd and Sudeep Pharma Ltd?

As of May 5, 2026, the Sanjivani Paranteral Ltd stock price is INR ₹167.5. On the other hand, Sudeep Pharma Ltd stock price is INR ₹685.9.

How do dividend payouts of Sanjivani Paranteral Ltd and Sudeep Pharma Ltd compare?

To compare the dividend payouts of Sanjivani Paranteral Ltd and Sudeep Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.